Welcome to LookChem.com Sign In|Join Free
  • or
9α-fluoro-11β,17α-dihydroxy-16α-methyl-3,20-dioxopregna-1,4-dien-21-yl β-D-galactopyranoside is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

92901-23-0

Post Buying Request

92901-23-0 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

92901-23-0 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 92901-23-0 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 9,2,9,0 and 1 respectively; the second part has 2 digits, 2 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 92901-23:
(7*9)+(6*2)+(5*9)+(4*0)+(3*1)+(2*2)+(1*3)=130
130 % 10 = 0
So 92901-23-0 is a valid CAS Registry Number.

92901-23-0Downstream Products

92901-23-0Relevant academic research and scientific papers

Drug Glycosydes: Potential Prodrugs for Colon-Specific Drug Delivery

Friend, David R.,Chang, George W.

, p. 51 - 57 (1985)

The influence of prodrug structure on specifity of glycoside/glycosidase based colon-specific drug delivery was studied by preparing nine steroid glycosides, measuring their relative lipophilicities, and hydrolyzing them with bacterial glycosidases from rat intestines.The 21-yl β-D-glucosides and galactosides of dexamethasone, prednisolone, hydrocortisone, and fludrocortisone and the 21-yl β-D-cellobioside of prednisolone were prepared by a modified Koenigs-Knorr reaction.The deacetylated glycoside prodrugs, along with the p-nitrophenyl derivatives of β-D-glucoside , galactoside, and cellobioside, were subjected to hydrolysis by the contents of the rat stomach, proximal small intestine (PSI), distal small intestine (DSI), and cecum.All the prodrugs were hydrolyzed slowly by PSI and stomach contents, more rapidly by contents of the DSI, and most rapidly by cecal contents.This is the basis of the site-specific drug delivery reported earlier (Friend, D.R.; Chang, G.W.J.Med.Chem. 1984, 27, 261).Furthermore, the prodrugs themselves had very different susceptibilities to hydrolysis.Hydrolysis rates catalyzed by DSI contents decreased in the following order: prednisolon-21-yl β-D-galactoside (10) > prednisolon-21-yl β-D-glucoside (2) > prednisolon-21-yl β-D-cellobioside (13) > dexamethason-21-yl β-D-galactoside (9) > dexamethason-21-yl β-D-glucoside (1).Hydrolysis of cellobioside 13 was only half that of glucoside 2 and one-fourth that of galactoside 10.Hydrolysis of all the prodrugs in cecal contents was rapid, with the exceptions of hydrocortison-21-yl β-D-glucoside (5) and fludrocortison-21-yl β-D-glucoside (7), which were hydrolyzed more slowly than the other glucoside prodrugs.Eadie-Hofstee plots for hydrolysis of the glucoside compounds suggested that bacterial β-D-glucosidase activity in the colon may be more heterogeneous in nature than β-D-galactosidase activity.Relative lipophilicities of the prodrugs and free steroids were compared by measuring their octanol-buffer partition coefficients (P).The logarithm of the P of cellobioside 13 (-0.56) was considerably lower than that of the other prodrugs, which ranged from 0.11 to 0.84.Log P of the free steroids ranged from 1.54 to 1.73.These relative rates of hydrolysis and relative lipophilicities, along with previously reported animal experiments, enable one to estimate the site specificity of glycoside prodrugs prior to extensive animal studies.

Compositions and methods for targeted enzymatic release of cell regulatory compounds

-

Page column 15, (2010/02/05)

Novel pro-drugs and methods for their use to alter the growth and biological characteristics of living cells, tissues, or whole organisms are described. The methods allow for selective activation of the pro-drugs at or near transformant host cells expressing a gene for an enzyme that activates the pro-drugs. Pro-drugs according to a preferred embodiment of the invention are conjugates of a bioactive compound and a chemical group that is capable of being cleaved from the bioactive compound by action of an enzyme. Methods according to this invention include, (a) introducing into targeted cells a gene encoding an enzyme and (b) administering a pro-drug, wherein the enzyme releases the pro-drug from conjugation. In a preferred embodiment of the invention, the gene encoding the enzyme is a marker gene.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 92901-23-0